alex revision
August 4th, 2010, 10:01 AM
Hepatitis B ups lymphoma risk: Study
Wed, 04 Aug 2010 13:47:36 GMT
http://www.presstv.com/detail.aspx?id=137442§ionid=3510210
Hepatitis B, long been linked with liver cancer, can place the sufferer at an increased risk of developing non-Hodgkin lymphoma in the long run, a new study says.
Previous studies have linked infection with hepatitis C virus (HCV) with non-Hodgkin lymphoma (NHL), adding that HCV treatment can contribute to effective hematological remission in those suffering from low-grade NHL.
According to the study published in the Lancet Oncology, individuals infected with HBV are at a doubled risk of developing NHL as the virus overstimulates the immune system to fight off the liver infection.
The chronic immune stimulation is also responsible for the development of DNA mutations in lymphocytes, a condition which promotes not only their proliferation but also progression to NHL.
Individuals with HBV infection are four times more likely to develop malignant immune-proliferation, a rare immune disorder related to NHL, the study found.
The higher risk of developing follicular or T-cell NHL, Hodgkin's lymphoma, multiple myeloma, or other types of leukemia, however, was not noted in these individuals.
While vaccinating against the virus does not affect the rate of developing the condition, applying the usual HBV treatments can effectively treat non-Hodgkin lymphoma patients.
Latest figures have revealed that 350 million individuals in different parts of the world are infected with hepatitis B virus (HBV), an infection which is responsible for 340,000 cases of liver cancer and between 500,000 and 1.2 million deaths per year.
Wed, 04 Aug 2010 13:47:36 GMT
http://www.presstv.com/detail.aspx?id=137442§ionid=3510210
Hepatitis B, long been linked with liver cancer, can place the sufferer at an increased risk of developing non-Hodgkin lymphoma in the long run, a new study says.
Previous studies have linked infection with hepatitis C virus (HCV) with non-Hodgkin lymphoma (NHL), adding that HCV treatment can contribute to effective hematological remission in those suffering from low-grade NHL.
According to the study published in the Lancet Oncology, individuals infected with HBV are at a doubled risk of developing NHL as the virus overstimulates the immune system to fight off the liver infection.
The chronic immune stimulation is also responsible for the development of DNA mutations in lymphocytes, a condition which promotes not only their proliferation but also progression to NHL.
Individuals with HBV infection are four times more likely to develop malignant immune-proliferation, a rare immune disorder related to NHL, the study found.
The higher risk of developing follicular or T-cell NHL, Hodgkin's lymphoma, multiple myeloma, or other types of leukemia, however, was not noted in these individuals.
While vaccinating against the virus does not affect the rate of developing the condition, applying the usual HBV treatments can effectively treat non-Hodgkin lymphoma patients.
Latest figures have revealed that 350 million individuals in different parts of the world are infected with hepatitis B virus (HBV), an infection which is responsible for 340,000 cases of liver cancer and between 500,000 and 1.2 million deaths per year.